Differential effects of treatment with the monovalent anti-VLA-4 inhibitor BIO 5192 on R-EAE. The indicated numbers of SJL mice were treated intraperitoneally daily for 21 treatments with either tris lactose vehicle or 600 μg of the small-molecule VLA-4 antagonist, BIO 5192, beginning prior to disease onset (A), during disease remission (B), or at the peak of the acute phase of disease (C). In Panel A, data are represented as mean clinical score versus day after priming. In panels B and C, treatment was tailored to each mouse depending on disease state and therefore data are represented as mean clinical score versus days prior to the first treatment, the first day of treatment, and days after treatment onset.